Trial record 1 of 1 for:    LCCC 1029
Previous Study | Return to List | Next Study

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

This study is currently recruiting participants.
Verified March 2014 by UNC Lineberger Comprehensive Cancer Center
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01298570
First received: February 16, 2011
Last updated: March 27, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2021
  Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
No publications provided by UNC Lineberger Comprehensive Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):